Veterinary Imaging Market Expected To Grow At High Cagr During Forecast Period 2019 – 2023

Market Scenario

The Global Veterinary Imaging Market is expected to register a CAGR of 7.14% to reach USD 2167.78 million by 2025. Veterinary imaging is the noninvasive method that helps to diagnose disease by making medical images of the veterinary body. We have various advanced imaging technology used for veterinary patients. Veterinary imaging instruments are used to diagnosis of chronic disease and getting medical images of animals. Notably, the increasing prevalence of zoonotic diseases, significant rise in pet insurance purchases, and increased number of veterinary practitioners are promoting the growth of the veterinary imaging market globally.

The market growth is mainly driven by increasing incidence of zoonotic diseases, increasing expenditure on pet insurance, and technological advancements in veterinary imaging. However, high procedure cost and lack of skilled veterinarians may slow the growth of the market.

Market Dynamics

Increasing expenditure on the pet is driving the growth of the Veterinary Imaging market. Pet insurance covers various minor to major medical expenses such as accidents, chronic conditions, wellness, and routine care coverage, medication coverage, diagnostic testing and imaging, others. Though pet insurance does not provide 100% coverage, it reimburses around 80% of the total pet medical expenses. According to the North American Pet Health Insurance Association (NAPHIA), North America’s pet health insurance growth was exceeded by 17.2% from 2014 to 2015. It is also reported that the total number of insured pets reached 1.6 million at the end of 2015.

Pet owners spend a lot on routine vet expenses and surgical vet visits. As per the data suggested by The American Pet Products Association (APPA), around 65% of the US population owns a pet, and the US pet industry expenditure in 2015 was USD 60.3 million, which is exceeded to USD 62.8 million. Thus, with the growing spending on animal healthcare, the demand for veterinary diagnosis and the equipment required for the same will also increase, which boosts the growth and veterinary imaging market size.

Segmentation

The global veterinary imaging market is segmented into product type, animal type, therapeutic area, and end user. On the basis of product type, the market is segmented into instruments, veterinary imaging reagents, and veterinary software. On the basis of animal type, it is segmented into small companion animals and large animals. On the basis of the therapeutic area, the veterinary imaging market segmented into orthopedics and traumatology, cardiology, neurology, and oncology. On the basis of end user, the Veterinary Imaging market segmented into hospitals & clinics, and academic institutes.

Regional Analysis

The global veterinary imaging market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2018, and the regional market is projected to register a CAGR of 7.62% during the forecast period. The larger share is majorly attributed to the growth in adoption of pet animals, increasing veterinary healthcare expenditure, increasing demand for pet insurance, and increasing pet ownership. According to the report published by the American Pet Products Association, from 2017 to 2018, 68% of the US households or 85 million families have a pet.

Europe is the second-largest market for veterinary imaging owing to the presence of large market players, innovative advanced technology, increasing companion animal ownership, and the presence of veterinaries.

The Asia Pacific region accounted the third-largest market owing to the presence of large animal population, increasing disposal income, increasing nuclear families preferring to have pets and increased investments by the American and European market giants in Asian countries such as China and India. India held a share of 15.9% in the Asia-Pacific veterinary imaging market in 2018.

The market in the Middle East and Africa is constrained due to poor development of the animal industry and the low productivity of the maximum breeds in the region.

Key Players

The prominent players in the global veterinary imaging market are Esaote SpA (Italy), GE Healthcare (US), Medical Imaging/IMCO, Inc. (US), BCF (Scotland), Fujifilm Holding Corporation (Japan), Heska Corporation (US), Diagnostic Imaging System, Inc. (US), Canon Inc. (Tokyo), Carestream Health (US), and Merry X-Ray (US).

The players operating in the global veterinary imaging market are focusing on product launches, along with expanding their global footprints by entering untapped markets.

• In March 2019, Esaote SpA launched the new ultrasound platform MyLabX8 for increasing efficiency of ultrasound machines and to maintain the workflow.
• In October 2018, GE Healthcare announced a strategic collaboration with SonoSim to encourage education and training about ultrasound devices. This collaboration is likely to help the company to increase its customer base.
• In June 2018, Fujifilm Holding Corporation acquired Irvine Scientific Sales Company, Inc. for USD 800 million. With this acquisition, Fujifilm is likely to enter into the cell culture media business.

Immunoassays in R&D Market Trends, Analysis And Review During 2019 To 2023

Market Scenario

The Global Immunoassay In R&D Market is expected to register a CAGR of 8.18% and is anticipated to reach USD 475.3 million by 2023. Immunoassays are analytical methods in which the quantitation of the analyte depends on the reaction of an antigen and an antibody. Immunoassays incorporate a variety of different labels for the detection of antibodies and antigens. These labels are generally chemically linked or conjugated to the desired antibody or antigen.

The increasing incidence of chronic and infectious diseases, growing research and development investment (R&D) activities, and technological advancements are the major factors boosting the growth of the market. Despite the drivers, the high cost of immunoassay procedures and the high price of immunoassay systems constrain the growth of the market.

Market Players

Market Research Future (MRFR) recognizes the following companies as the key players in the global immunoassay in R&D market that includes Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (Germany), Becton, Dickinson and Company (US), Danaher Corporation (US), bioMérieux Inc. (France), Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Sysmex Corporation (Japan), and Abcam plc (United Kingdom).

Segment Analysis

The global immunoassay in R&D market has been segmented into type, application, and end user. By type, the market has been segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot Assay (ELISpot), Radioimmunoassay (RIA), Chemiluminescence (CLIA), Fluoroimmunoassay, and Others. On the basis of application, the market has been segmented into infectious diseases, cancer research, endocrinology, autoimmune diseases, and others. By end-user, the market has been segmented pharmaceutical and biotechnology companies, academic institutions and laboratories, and others

Regional Analysis

Geographically, the Americas is expected to dominate the global immunoassay in R&D market. The market growth is attributed to the increasing number of research projects in laboratories, growing adoption of advanced technology in research, and the growing prevalence of several diseases. The European market for immunoassay in R&D is expected to be the second-largest market due to the growing adoption in diagnostic measures is expected to boost the growth of the market in this region.

Moreover, the companies operating in the market are particularly focusing on mergers and acquisition which is expected to support the market growth. Asia-Pacific is estimated to be the fastest growing market due to the developing healthcare infrastructure and increasing disposable income. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the Asia-Pacific region, South Korea accounted for a market share of 10.1% in 2017. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.

Key Findings of the Study:

• Global immunoassay in R&D market is projected to reach USD 3 million by 2023 with 8.18% CAGR during the review period of 2018 to 2023

• Americas accounted for the largest immunoassay in R&D market share in the region due to the increasing number of research projects and the growing prevalence of chronic diseases

• The pharmaceutical and biotechnology companies segment accounted for a market value of USD 174.3 million in 2017

Injectable Drug Delivery Devices Market - Demand, Growth, Opportunities And Analysis Of Top Key Player Forecast To 2023

Market scenario:

The Global Injectable Drug Delivery Devices Market is expected to register 11.3% CAGR and is anticipated to reach USD 17,401.8 million by 2023. Injectable drug delivery devices, including conventional syringes, needle-free injectors, and auto and pen injectors, have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The global market for injectable drug delivery devices has witnessed continuously increasing R&D. As a result, the market is fragmented into various high-end and technologically advanced products. Following the illustrated course, it is projected that an increasing prevalence of chronic diseases, growing adoption of self-injectable devices, and rising FDA approvals drive the market growth. However, the presence of cross-contamination and increasing cost of high-end products are estimated to restrain the market growth during the forecast period.

Market Dynamics

The global injectable drug delivery devices prevalence of chronic diseases such as diabetes, heart diseases, multiple sclerosis, cancer, and arthritis have increased. According to the statistical report published by the American Diabetes Association, in 2017, ~30.3 million, i.e., 9.4% of the total population within the US had diabetes in 2015. Moreover, the fact sheet of 2018 published by the World Health Organization estimates cancer to be the second leading cause of death across the globe. The disease is estimated to cause ~9.6 million deaths in 2018. The other factors that are driving the global injectable drug delivery devices market are growing adoption of self-injectable devices, Rising FDA approvals for the drug delivery devices, and others.

Global Injectable Drug Delivery Devices Market Size, by Site of Delivery, 2017 & 2023 (USD Million)
Segmentation

The global Injectable drug delivery devices market has been segmented into devices, therapeutic application, usage pattern, site of delivery, distribution channel, and facility of use.

Based on device, the global market is divided into conventional injection devices and self-injection devices.

Based on therapeutic application, the global market is segmented into autoimmune diseases, hormonal disorders, and cancer.

Based on usage pattern, the global market is divided into curative pattern and immunization.

Based on site of delivery, the global market is segmented into intramuscular, subcutaneous, and intradermal.

Based on distribution channel, the global market is divided into hospital & retail pharmacies and online platforms.

Based on facility of use, the global market is segmented into hospitals and clinics and home care settings.

Key Players

The prominent players in the global Injectable drug delivery devices market are Eisai Co., Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson Services Inc., Mylan N.V., Novartis AG, Novo Nordisk, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, and Inovio Pharmaceuticals Inc.

Regional Analysis

The global Injectable drug delivery devices market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is anticipated to dominate the global injectable drug delivery devices market owing to the rising awareness about the condition and high healthcare expenditure. The region is expected to reach USD 17,401.8 million by 2023 with a CAGR of 11.3% from2018 to 2023. The Americas accounted largest regional market owing to the growing biotechnology industry, the ever-increasing prevalence of cancer and diabetes, and a well-developed healthcare sector.  

Europe accounted for the second-largest market share in 2017 due to extensive R&D in healthcare, increasing funding, and growing adoption of the devices within the region.

On the other hand, the Middle East & Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.

Precision Medicine Market Volume Forecast And Value Chain Analysis 2019

The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.

The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2025. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2025.

Precision medicine evolved from the concept that same medicine cannot function equally for two different individuals with the same disease as they have different gene structure. At the same time, medication depends on how well patients can respond to its dosage. Hence, the need for precision medicine. Market Research Future (MRFR), in their report, has included various drivers and segments that can produce a reliable prediction for the future market. Prevalent diseases such as cancer, diabetes, and others are boosting the precision medicine market as treatment of such diseases gets a better result with personalized medicine structure. Furthermore, its impact can significantly lower the cost of treatment.

However, a personal data breach can be seen as a major precision medicine market growth prohibition. The diagnostic cost can incur a high cost, stringent government policies, the risk with hardware and software failure, and lack of medical framework can hold back the market during the forecast period.

Key Players for Global Precision Medicine Market:

Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine

Key Findings:

• The global precision medicine market is expected to reach USD 88.64 billion by 2025.
• By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2025.
• By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2025.

Segmentation

The global precision medicine market has been segmented into ecosystem players, sub-markets, and therapeutics.

Based on ecosystem players, the global market has been segmented into pharmaceuticals and biotechnology companies, diagnostic companies, healthcare IT specialists/big data companies, and clinical laboratories. The diagnostic tool companies segment accounted for a market value of USD 16.27 million in 2017.

Based on sub-markets, the global market has been segmented into companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics (PGX), molecular diagnostics, and others.

Based on therapeutics, the global market has been segmented cancer/oncology, cardiovascular disease (CVD), central nervous system, infectious diseases, and others.

Regional Analysis

Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.

Pericarditis Market Expected To Boost During 2019 To 2023

Market Scenario:

Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.

The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the market.

The Global Pericarditis Market is expected to register 7.96% CAGR and is anticipated to reach USD 2,741.39 Million by 2023.

Market Dynamics

The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.

Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.

Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.

The market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.

Segmentation

The global pericarditis market has been segmented into type, application, and end user. 

Based on type, the global market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.

Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.

Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.

Key Players

The prominent players in the global pericarditis market are Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the other major players in the global market.

Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.

Regional Analysis

The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is estimated to dominate the global pericarditis market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.

The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.

Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.

Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.

Key Updates

• In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.

• In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.

• In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.

Pathological Microscopes Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario

The growth of the healthcare sector in conjunction with the rising prevalence of diseases is expected to create demand for advanced equipment over the next couple of years. A study conducted by Market Research Future (MRFR) on the pathological microscopes market projects that a CAGR of 4.50% over the assessment period 2018 to 2023. The report further underlines that the market is expected to scale a valuation of USD 523.20 Mn towards the close of 2023.

The increasing burden of diseases such as cancer, diabetes, tuberculosis, etc. is anticipated to intensify the demand for pathological equipment that facilitates early detection and diagnosis. It is projected to pave the way for innovation and development of devices that offer accuracy. This, in turn, is anticipated to have a favorable impact on the growth pattern of the pathological microscopes market in the years to come.

The automation drive witnessed in the laboratories is also projected to accelerate revenue creation for market participants. Again, the increasing count of laboratories and pathology labs are expected to propel the expansion of the pathological microscopes market over the next few years.

Competitive Analysis

Microscope manufacturers in the pathological microscopes market include Nikon Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Olympus Corporation (Japan), ZEISS International (Germany), Labomed, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Euromex Microscopen BV (The Netherlands), Bruker Corporation (U.S.), Sakura Finetek USA, Inc. (U.S.), and Celestron LLC (U.S.).

The players are focusing on integrating new technologies to expedite the diagnosis rate associated with microscopes and lower the mortality rate. Collaborations, new product launches, and partnerships are strategies being adopted to gain a larger market share.

Segmentation

The pathological microscopes market is segmented by type, application, and end-user.

By type, electron microscope held close to 41.4% share in 2017, followed by optical microscope (18.8%), compound microscope (13.5%), digital microscope (5.4%), fluorescence microscope (4.4%), and others (16.5%). Electron microscopes can generate nearly USD 217.81 million by 2023 owing to their application in life sciences. Prevalence of diseases such as anemia and leukemia which require the need of electron microscopes lend credence to the segment valuation. But digital microscopes can exhibit the highest CAGR of 5.01% during the forecast period to accumulate USD 28.90 million for the pathological microscopes market by 2023.

By end-user, pathology & diagnostic laboratories accounted for 45.2% market share in 2017, followed by hospitals & clinics (38.6%), forensic laboratories (11.5%), and others (4.7%). Hospitals & clinics will be the biggest end-user of the pathological microscopes market by 2023. It can generate USD 206.25 million by the end of the forecast period owing to the setup of various branches of hospital chains to handle high patient volume. On the other hand, pathology & diagnostic laboratories can generate USD 239.73 million by 2023 thanks to possessing various skilled personnel and use of hematology, clinical microbiology, and molecular pathology for rapid diagnosis of diseases.

By application, bodily fluids accounted for 79.4% share of the pathological microscopes market in 2017, followed by tissue scanning (12.7%), and others (7.9%). Bodily fluids can generate USD 418.84 million for the pathological microscopes market by 2023. This can be attributed to use of fluid samples to identify the presence of diseases such as tuberculosis in the human body. High prevalence of blood disorders is driving the segment growth. On the other hand, tissue scanning is touted to accumulate USD 67.94 million by 2023. High prevalence of cancer and use of digital microscopes to detect abnormal tissue growth can fuel the segment growth.

Regional Analysis

The global pathological microscopes market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas is expected to gain control over the maximum market share during the review period. The regional market is projected to touch a valuation of USD 190.98 Mn by the end of 2023. The advancements of laboratories being observed in the region are expected to drive the growth of the pathological microscopes market in the nearby future.

Asia Pacific is projected to exhibit healthy growth owing to the rapid developments in the healthcare sector. The pathological microscopes market in the region is anticipated to attract massive investments over the next couple of years, thus, augmenting the market.

Industry News:

In March 2019, Nikon Instruments Inc., a leader in advanced optical instruments, has announced a partnership with OptraSCAN, On-Demand Digital Pathology Solution Provider, for the launch of OS-15-N, a digital slide scanning system that features Nikon optics.

In January 2019, Roche, a Swiss multinational healthcare company, has announced the introduction of its uPath enterprise software for digital pathology.

Microbiology Testing Market Value Share, Supply Demand, Share And Value Chain 2019

Global Microbiology Testing Market - Overview

Microbiology testing has emerged as one of the rapidly changing and growing segment of healthcare over the past few years. Microbiology testing deals with the study of microbial germs and their clinical applications for the improvement of health. Microbiology testing is concern with the diagnosis, prevention and treatment of various infectious diseases such as, sexually respiratory infections, urinary tract infections, gastrointestinal infections, sexually transmitted infections, and many others. These diseases can be spread from one person to another, directly or indirectly.

According to a recent study published by the Market Research Future analysts, the global microbiology testing market is growing at a double digit growth rate; mainly due to factors such as technological advancements, rising cases of infectious diseases, surveillance programs for disease control, and rising stringency of standards.  On the other hand, erroneous results produced during the testing, and heavy costs of the tests and instruments have created some obstacles in the growth of this market in all parts of the world.

Global Microbiology Testing Market - Competitive Analysis

There are large number of companies involved in the development of the products, instruments, and test kits for the microbiology testing which are now being used in majority part of the developed countries. Global market for microbiology testing is majorly dominated by Biomérieux SA with more than 40% of market share in 2016.

Major companies are adopting a specific strategy to enter and create unique space in this market. The different strategies includes, product launch, agreement and collaboration, partnership and expansion, joint venture and strategic alliance etc. All major players are focusing on new product development to provide new and innovative solutions to the market.

Biomérieux SA offers a comprehensive range diagnostic solutions which include Microbiology lab instruments, reagents and software. The products of the company is mainly used for diagnosing infectious diseases. In 2016, BioMérieux announced the acquisition of Hyglos. With this acquisition, the company plans to strengthen its position in the market.

Some of the major developments in this segment came from the Roche Diagnostics. In April 2017, the company received FDA clearance for the CINtec Histology test. This test is the only clinically validated p16 biomarker test. The CINtec Histology test will help physicians make informed decisions as to the best course of care for patients with high-grade pre-cancerous cervical disease. Back in 2015, Roche acquired GeneWEAVE to strengthen offerings in microbiology diagnostics.

The global market consist of players such as Alere (US), BD (US), Beckman Coulter, Inc. (US), Biomérieux SA (France), Cepheid (US), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific Inc. (US). These are the prominent players at the forefront of competition in the global microbiology testing market and are profiled in MRFR Analysis report.

Global Microbiology Testing Market - Regional Analysis

In 2016, North America and Europe were holding more than half market share of global microbiology testing market. Increasing funding for R&D is major driving force for the market growth. The funding for microbiology testing in US is one of the highest as compared to other countries. Rapid adoption of advanced products and techniques are driving the growth for North America market. Increasing cases of infectious diseases are promoting the research related activities in this region. Independent laboratories are dominating the North America market by adopting new technologies and trends.

European market is second highest revenue generator after North America. Europe microbiology testing market has benefited by the presence of some major players in this region. Moreover, increasing innovation and changing laboratory practices are driving the growth for Europe microbiology testing market. Microbiology testing have huge and increasing demand not only in developed countries but also in developing countries like China, India, and Spain.

Rising prevalence of respiratory infections are increasing burden on Asia-Pacific healthcare system. Being a large population base, increasing aging population, and increasing use of technology in healthcare, China microbiology testing market is growing at rapid pace. China is expected to grow at a CAGR of 12.8% during the forecast period. The number of independent laboratories are rapidly increasing such as KingMed Diagnostics and Dian Diagnostics. KingMed Diagnostics is largest chain of independent laboratories in china.

The Middle East and Africa microbiology testing market is growing dramatically due increasing prevalence of various infectious diseases like Ebola. This region is carrying greatest burden of infectious disease. Sexually transmitted diseases are also major public health problem in this region. There are some factors are affecting the microbiology testing market in this region such as, limited access to the healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, limited availability of products etc.